What is SAGA Diagnostics?
SAGA Diagnostics AB is a pioneering company focused on personalized cancer diagnostics and disease monitoring. The firm specializes in advanced molecular genetic testing, utilizing both tissue biopsies and innovative non-invasive "liquid biopsies" derived from samples such as blood. This approach aims to provide more precise and accessible diagnostic solutions for cancer patients.
How much funding has SAGA Diagnostics raised?
SAGA Diagnostics has raised a total of $12.5M across 1 funding round:
Series A
$12.5M
Series A (2021): $12.5M with participation from Segulah Medical Acceleration and Hadean Ventures
Key Investors in SAGA Diagnostics
Segulah Medical Acceleration
Segulah Medical Acceleration is likely a venture capital firm or investment group focused on accelerating growth in the medical and healthcare technology sectors, potentially specializing in early-stage or growth-stage companies.
Hadean Ventures
Hadean Ventures appears to be an investment entity with a focus on the life sciences and healthcare industries, likely providing capital and strategic guidance to companies developing innovative medical solutions.
What's next for SAGA Diagnostics?
With the recent major strategic investment and substantial total funding, SAGA Diagnostics is poised for significant expansion and further development of its diagnostic technologies. The company is likely to focus on scaling its operations, enhancing its molecular genetic testing capabilities, and broadening the reach of its liquid biopsy solutions. This enterprise-level funding suggests a strategic push towards market leadership and the potential for new partnerships or clinical integrations to accelerate growth in the personalized oncology sector.
See full SAGA Diagnostics company page
